Publicaciones en las que colabora con Jaime Sanz Caballer (13)

2024

  1. Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO

    Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 988.e1-988.e11

  2. Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party

    Cancer, Vol. 130, Núm. 18, pp. 3123-3136

2023

  1. Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis

    Leukemia, Vol. 37, Núm. 7, pp. 1511-1520

  2. Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT (Journal of Hematology & Oncology, (2023), 16, 1, (58), 10.1186/s13045-023-01450-4)

    Journal of Hematology and Oncology

  3. Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x)

    Bone Marrow Transplantation

  4. Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study

    Transplantation and Cellular Therapy, Vol. 29, Núm. 12, pp. 747.e1-747.e10

  5. Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT

    Journal of Hematology and Oncology, Vol. 16, Núm. 1

  6. Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

    Bone Marrow Transplantation, Vol. 58, Núm. 6, pp. 673-679

2022

  1. Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups

    Frontiers in Immunology, Vol. 13

  2. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial

    The Lancet Haematology, Vol. 9, Núm. 1, pp. e14-e25

2021

  1. Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation

    Annals of Hematology, Vol. 100, Núm. 2, pp. 541-553

2019

  1. Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders

    AIDS, Vol. 33, Núm. 9, pp. 1441-1447

2017

  1. Single umbilical cord blood with or without CD341 cells from a third-party donor in adults with leukemia

    Blood Advances, Vol. 1, Núm. 15, pp. 1047-1055